FR3023290B1 - Derives de flavaglines - Google Patents

Derives de flavaglines

Info

Publication number
FR3023290B1
FR3023290B1 FR1456474A FR1456474A FR3023290B1 FR 3023290 B1 FR3023290 B1 FR 3023290B1 FR 1456474 A FR1456474 A FR 1456474A FR 1456474 A FR1456474 A FR 1456474A FR 3023290 B1 FR3023290 B1 FR 3023290B1
Authority
FR
France
Prior art keywords
flavaglines
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1456474A
Other languages
English (en)
French (fr)
Other versions
FR3023290A1 (fr
Inventor
Frederic Marion
El Bachir Kaloun
Frederic Lieby-Muller
Michel Perez
Jean Philippe Annereau
Laurent Creancier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pierre Fabre Medicament SA
Original Assignee
Pierre Fabre Medicament SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR1456474A priority Critical patent/FR3023290B1/fr
Application filed by Pierre Fabre Medicament SA filed Critical Pierre Fabre Medicament SA
Priority to US15/323,650 priority patent/US10047064B2/en
Priority to EP18187037.9A priority patent/EP3418273B1/fr
Priority to DK15733767.6T priority patent/DK3164393T3/en
Priority to ES18187037T priority patent/ES2908225T3/es
Priority to PCT/EP2015/065294 priority patent/WO2016001441A1/fr
Priority to PL18187037.9T priority patent/PL3418273T3/pl
Priority to TR2018/19805T priority patent/TR201819805T4/tr
Priority to PL15733767T priority patent/PL3164393T3/pl
Priority to ES15733767T priority patent/ES2700156T3/es
Priority to JP2017500083A priority patent/JP6637954B2/ja
Priority to EP21213303.7A priority patent/EP3998257A1/fr
Priority to DK18187037.9T priority patent/DK3418273T3/da
Priority to EP15733767.6A priority patent/EP3164393B1/fr
Publication of FR3023290A1 publication Critical patent/FR3023290A1/fr
Application granted granted Critical
Publication of FR3023290B1 publication Critical patent/FR3023290B1/fr
Priority to US15/829,630 priority patent/US10519125B2/en
Priority to JP2019230768A priority patent/JP6951406B2/ja
Priority to JP2021154798A priority patent/JP7340574B2/ja
Priority to JP2023137552A priority patent/JP2023159393A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Furan Compounds (AREA)
FR1456474A 2014-07-04 2014-07-04 Derives de flavaglines Active FR3023290B1 (fr)

Priority Applications (18)

Application Number Priority Date Filing Date Title
FR1456474A FR3023290B1 (fr) 2014-07-04 2014-07-04 Derives de flavaglines
EP21213303.7A EP3998257A1 (fr) 2014-07-04 2015-07-06 Dérivés de flavaglines
DK15733767.6T DK3164393T3 (en) 2014-07-04 2015-07-06 Flavagline derivatives
ES18187037T ES2908225T3 (es) 2014-07-04 2015-07-06 Derivados de flavaglinas
PCT/EP2015/065294 WO2016001441A1 (fr) 2014-07-04 2015-07-06 Dérivés de flavaglines
PL18187037.9T PL3418273T3 (pl) 2014-07-04 2015-07-06 Pochodne flawaglin
TR2018/19805T TR201819805T4 (tr) 2014-07-04 2015-07-06 Flavaglin türevleri̇.
PL15733767T PL3164393T3 (pl) 2014-07-04 2015-07-06 Pochodne flawaglin
ES15733767T ES2700156T3 (es) 2014-07-04 2015-07-06 Derivados de flavaglinas
EP15733767.6A EP3164393B1 (fr) 2014-07-04 2015-07-06 Dérivés de flavaglines
US15/323,650 US10047064B2 (en) 2014-07-04 2015-07-06 Flavagline derivatives
EP18187037.9A EP3418273B1 (fr) 2014-07-04 2015-07-06 Dérivés de flavaglines
JP2017500083A JP6637954B2 (ja) 2014-07-04 2015-07-06 フラバグリン誘導体
DK18187037.9T DK3418273T3 (da) 2014-07-04 2015-07-06 Derivater af flavagliner
US15/829,630 US10519125B2 (en) 2014-07-04 2017-12-01 Flavagline derivatives
JP2019230768A JP6951406B2 (ja) 2014-07-04 2019-12-20 フラバグリン誘導体
JP2021154798A JP7340574B2 (ja) 2014-07-04 2021-09-22 フラバグリン誘導体
JP2023137552A JP2023159393A (ja) 2014-07-04 2023-08-25 フラバグリン誘導体

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1456474A FR3023290B1 (fr) 2014-07-04 2014-07-04 Derives de flavaglines

Publications (2)

Publication Number Publication Date
FR3023290A1 FR3023290A1 (fr) 2016-01-08
FR3023290B1 true FR3023290B1 (fr) 2016-08-19

Family

ID=52016681

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1456474A Active FR3023290B1 (fr) 2014-07-04 2014-07-04 Derives de flavaglines

Country Status (9)

Country Link
US (2) US10047064B2 (enExample)
EP (3) EP3164393B1 (enExample)
JP (4) JP6637954B2 (enExample)
DK (2) DK3418273T3 (enExample)
ES (2) ES2908225T3 (enExample)
FR (1) FR3023290B1 (enExample)
PL (2) PL3164393T3 (enExample)
TR (1) TR201819805T4 (enExample)
WO (1) WO2016001441A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3023290B1 (fr) * 2014-07-04 2016-08-19 Pf Medicament Derives de flavaglines
ES2974439T3 (es) 2015-11-25 2024-06-27 Effector Therapeutics Inc Compuestos inhibidores de EIF4-A y métodos relacionados con los mismos
LT3643707T (lt) * 2017-06-19 2022-05-25 Futurechem Co., Ltd. 18f žymėtas junginys, skirtas prostatos vėžio diagnostikai ir jo panaudojimas
AU2019221837B2 (en) * 2018-02-19 2024-08-01 Memorial Sloan-Kettering Cancer Center Agents and methods for treating dysproliferative diseases
WO2020076889A1 (en) * 2018-10-09 2020-04-16 The Research Institute At Nationwide Children's Hospital Anticancer rocaglamide derivatives
WO2020086562A1 (en) * 2018-10-22 2020-04-30 Trustees Of Boston University Compositions and methods for inhibiting viral infection
IL291979B1 (en) 2019-10-10 2025-08-01 Cellectar Biosciences Inc Phospholipid-flavagline conjugates and methods of using the same for targeted cancer therapy
WO2025104293A1 (en) * 2023-11-17 2025-05-22 Gustave Roussy Transfert Inhibitors of eif4a and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ866500A0 (en) * 2000-07-05 2000-08-03 Exgenix Operations Pty Ltd Therapeutic compounds and methods
DE102004024504A1 (de) * 2004-05-18 2006-02-16 Bayer Healthcare Ag Neue Cylopenta[b]benzofuran-Derivate und ihre Verwendung
WO2007139749A2 (en) * 2006-05-22 2007-12-06 Trustees Of Boston University Asymmetric synthesis of rocaglamides via enantioselective photocycloaddition mediated by chiral bronsted acids
EP2189453A1 (en) * 2008-11-25 2010-05-26 Université Louis Pasteur Rocaglaol derivatives as cardioprotectant agents
CN102300568A (zh) 2008-12-05 2011-12-28 赢泰医药科技发展有限公司 Hif-1蛋白积聚的抑制剂
FR3023290B1 (fr) * 2014-07-04 2016-08-19 Pf Medicament Derives de flavaglines

Also Published As

Publication number Publication date
ES2908225T3 (es) 2022-04-28
JP6637954B2 (ja) 2020-01-29
JP2023159393A (ja) 2023-10-31
EP3418273B1 (fr) 2022-01-12
US10519125B2 (en) 2019-12-31
US20180086729A1 (en) 2018-03-29
WO2016001441A1 (fr) 2016-01-07
JP2022000455A (ja) 2022-01-04
JP6951406B2 (ja) 2021-10-20
EP3164393B1 (fr) 2018-09-19
PL3164393T3 (pl) 2019-03-29
ES2700156T3 (es) 2019-02-14
US10047064B2 (en) 2018-08-14
DK3418273T3 (da) 2022-03-21
PL3418273T3 (pl) 2022-08-01
FR3023290A1 (fr) 2016-01-08
JP2020063289A (ja) 2020-04-23
JP7340574B2 (ja) 2023-09-07
EP3418273A1 (fr) 2018-12-26
DK3164393T3 (en) 2019-01-21
EP3164393A1 (fr) 2017-05-10
JP2017519796A (ja) 2017-07-20
US20170137400A1 (en) 2017-05-18
EP3998257A1 (fr) 2022-05-18
TR201819805T4 (tr) 2019-01-21

Similar Documents

Publication Publication Date Title
DK3319956T3 (da) Substituerede oxopyridinderivater
LT3204359T (lt) Tetrahidroizochinolino dariniai
HUE048321T2 (hu) Karabazol származékok
PT3457851T (pt) Derivados de sobetiroma
HUE050974T2 (hu) Eljárás pirimidinszulfamid-származékok elõállítására
LT3402792T (lt) Chinolin-2-ono dariniai
DK3132009T3 (da) Fremgangsmåde
DK3231803T3 (da) Dihydroindolizinonderivat
DK3283210T3 (da) Fremgangsmåde
LT3371168T (lt) Indolin-2-ono dariniai
FR3023290B1 (fr) Derives de flavaglines
DK3143018T3 (da) Carboxamidderivater
IL250613B (en) Substituted bicyclic compounds
PT3131898T (pt) Derivados de fluoroalquilfluoreno
IL254502B (en) Solid forms of menaquinols
IL248608A0 (en) Heparan sulphates
LT3097076T (lt) Nauji cip-eikozanoidų dariniai
BR112016026725A2 (pt) Derivados de aminoéster
FR3024647B1 (fr) Transat de puericulture
FR3022129B1 (fr) Baignoire de puericulture
IL252908A0 (en) Fumagillol derivatives
DK3285588T3 (da) Fremgangsmåde
PL3350308T3 (pl) Zastosowanie włókna liocelowego
HRP20182065T1 (hr) Postupak za pripremu penama
ES1109880Y (es) Estructura de toldo

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20160108

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6

PLFP Fee payment

Year of fee payment: 7

PLFP Fee payment

Year of fee payment: 8

PLFP Fee payment

Year of fee payment: 9

PLFP Fee payment

Year of fee payment: 10

PLFP Fee payment

Year of fee payment: 11

PLFP Fee payment

Year of fee payment: 12